Literature DB >> 24956412

Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy.

Ivan Jambor1, Esa Kähkönen, Pekka Taimen, Harri Merisaari, Jani Saunavaara, Kalle Alanen, Branislav Obsitnik, Heikki Minn, Viera Lehotska, Hannu J Aronen.   

Abstract

PURPOSE: To find the diagnostic accuracy of 3T multiparametric magnetic resonance imaging (mpMRI) and mpMRI targeted transrectal ultrasound (TRUS)-guided biopsy using visual coregistration (TB) in patients with elevated prostate-specific antigen (PSA), normal digital rectal examination, and no previous biopsy.
MATERIALS AND METHODS: Fifty-five patients at two institutions underwent mpMRI, consisting of anatomical T2 -weighted imaging (T2 W), diffusion-weighted imaging (DWI), proton magnetic resonance spectroscopy ((1) H-MRS), and dynamic contrast-enhanced MRI (DCE-MRI), followed by TB in addition to 12 core systematic TRUS-guided biopsy (SB). Histopathological scorings of biopsy (n = 38) and prostatectomy (n = 17) specimens were used as the reference standard for calculation of diagnostic accuracy values. Clinically significant prostate cancer (SPCa) was defined as 3 mm core length of Gleason score 3+3 or any Gleason grade 4.
RESULTS: The sensitivity, specificity, accuracy, and area under the curve (AUC) values for the detection of SPCa on the sextant level for T2 W+DWI+(1) H-MRS+DCE-MRI were 72%, 89%, 85%, and 0.81, respectively. The corresponding values for T2 wi+DWI were 61%, 96%, 87%, and 0.79, respectively. The overall PCa detection rate per core in 53 patients was 21% (138 of 648 cores) for SB and 43% (33 of 77 cores) for TB (P < 0.001).
CONCLUSION: Prebiopsy mpMRI is an accurate tool for PCa detection and biopsy targeting in patients with elevated PSA.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  multiparametric MRI; prostate cancer; targeted prostate biopsy

Mesh:

Substances:

Year:  2014        PMID: 24956412     DOI: 10.1002/jmri.24682

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  14 in total

Review 1.  Current trends and new frontiers in focal therapy for localized prostate cancer.

Authors:  Melissa H Mendez; Daniel Y Joh; Rajan Gupta; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2015-06       Impact factor: 3.092

2.  Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial).

Authors:  Ivan Jambor; Anna Kuisma; Esa Kähkönen; Jukka Kemppainen; Harri Merisaari; Olli Eskola; Jarmo Teuho; Ileana Montoya Perez; Marko Pesola; Hannu J Aronen; Peter J Boström; Pekka Taimen; Heikki Minn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-16       Impact factor: 9.236

3.  Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.

Authors:  Frank-Jan H Drost; Daniël F Osses; Daan Nieboer; Ewout W Steyerberg; Chris H Bangma; Monique J Roobol; Ivo G Schoots
Journal:  Cochrane Database Syst Rev       Date:  2019-04-25

4.  Tournament leave-pair-out cross-validation for receiver operating characteristic analysis.

Authors:  Ileana Montoya Perez; Antti Airola; Peter J Boström; Ivan Jambor; Tapio Pahikkala
Journal:  Stat Methods Med Res       Date:  2018-08-20       Impact factor: 3.021

5.  Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multi-institutional study.

Authors:  Shoshana B Ginsburg; Ahmad Algohary; Shivani Pahwa; Vikas Gulani; Lee Ponsky; Hannu J Aronen; Peter J Boström; Maret Böhm; Anne-Maree Haynes; Phillip Brenner; Warick Delprado; James Thompson; Marley Pulbrock; Pekka Taimen; Robert Villani; Phillip Stricker; Ardeshir R Rastinehad; Ivan Jambor; Anant Madabhushi
Journal:  J Magn Reson Imaging       Date:  2016-12-19       Impact factor: 4.813

6.  Prostate cancer detection among readers with different degree of experience using ultra-high b-value diffusion-weighted Imaging: Is a non-contrast protocol sufficient to detect significant cancer?

Authors:  D Hausmann; N Aksöz; J von Hardenberg; T Martini; N Westhoff; S Buettner; S O Schoenberg; P Riffel
Journal:  Eur Radiol       Date:  2017-08-10       Impact factor: 5.315

Review 7.  Multiparametric magnetic resonance imaging for prostate cancer: A review and update for urologists.

Authors:  Sangjun Yoo; Jeong Kon Kim; In Gab Jeong
Journal:  Korean J Urol       Date:  2015-06-30

Review 8.  Prostate MRI - an update for the referring urologist.

Authors:  Marcin Czarniecki; Maciej Jakuciński; Leszek Królicki
Journal:  Cent European J Urol       Date:  2016-01-22

9.  Is dynamic contrast enhancement still necessary in multiparametric magnetic resonance for diagnosis of prostate cancer: a systematic review and meta-analysis.

Authors:  Zhen Liang; Rui Hu; Yongjiao Yang; Neng An; Xiaoxin Duo; Zheng Liu; Shangheng Shi; Xiaoqiang Liu
Journal:  Transl Androl Urol       Date:  2020-04

Review 10.  Optimization of prostate MRI acquisition and post-processing protocol: a pictorial review with access to acquisition protocols.

Authors:  Ivan Jambor
Journal:  Acta Radiol Open       Date:  2017-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.